Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Carla J Mathias

Showing results (11-20 of 19) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 19 results.
Nuclear Medicine and Biology|June 29, 2002
Synthesis and evaluation of 99mTc(CO)(3)-DTPA-folate as a folate-receptor-targeted radiopharmaceuticalDavid P Trump, Carla J Mathias, Zhenfan Yang, et al.
Nuclear Medicine and Biology|March 27, 2007
Assessment of Cu-ETS as a PET radiopharmaceutical for evaluation of regional renal perfusionMark A Green, Carla J Mathias, Lynn R Willis, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|December 20, 2014
Whole-body PET/CT evaluation of tumor perfusion using generator-based 62Cu-ethylglyoxal bis(thiosemicarbazonato)copper(II): validation by direct comparison to 15O-water in metastatic renal cell carcinomaJames W Fletcher, Theodore F Logan, Jacob A Eitel, et al.
Nuclear Medicine and Biology|December 25, 2016
Estimation of radiation dosimetry for <sup>68</sup>Ga-HBED-CC (PSMA-11) in patients with suspected recurrence of prostate cancerMark A Green, Jacob A Eitel, James W Fletcher, et al.
Molecular Imaging and Biology|August 21, 2019
[<sup>68</sup>Ga]Ga-P16-093 as a PSMA-Targeted PET Radiopharmaceutical for Detection of Cancer: Initial Evaluation and Comparison with [<sup>68</sup>Ga]Ga-PSMA-11 in Prostate Cancer Patients Presenting with Biochemical RecurrenceMark A Green, Gary D Hutchins, Clinton D Bahler, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 7, 2003
Evaluation of 111In-DTPA-folate as a receptor-targeted diagnostic agent for ovarian cancer: initial clinical resultsBarry A Siegel, Farrokh Dehdashti, David G Mutch, et al.
Urologic Oncology|November 4, 2022
Assessing extra-prostatic extension for surgical guidance in prostate cancer: Comparing two PSMA-PET tracers with the standard-of-careClinton D Bahler, Mark A Green, Mark A Tann, et al.
Nuclear Medicine and Biology|September 23, 2003
Preparation of 66Ga- and 68Ga-labeled Ga(III)-deferoxamine-folate as potential folate-receptor-targeted PET radiopharmaceuticalsCarla J Mathias, Michael R Lewis, David E Reichert, et al.
The Journal of Urology|May 24, 2024
Comparing Magnetic Resonance Imaging and Prostate-Specific Membrane Antigen-Positron Emission Tomography for Prediction of Extraprostatic Extension of Prostate Cancer and Surgical Guidance: A Prospective Nonrandomized Clinical TrialClinton D Bahler, Isamu Tachibana, Mark Tann, et al.
Pageof 2

Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
Nuclear Medicine and Biology|June 29, 2002
Synthesis and evaluation of 99mTc(CO)(3)-DTPA-folate as a folate-receptor-targeted radiopharmaceuticalDavid P Trump, Carla J Mathias, Zhenfan Yang, et al.
Nuclear Medicine and Biology|March 27, 2007
Assessment of Cu-ETS as a PET radiopharmaceutical for evaluation of regional renal perfusionMark A Green, Carla J Mathias, Lynn R Willis, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|December 20, 2014
Whole-body PET/CT evaluation of tumor perfusion using generator-based 62Cu-ethylglyoxal bis(thiosemicarbazonato)copper(II): validation by direct comparison to 15O-water in metastatic renal cell carcinomaJames W Fletcher, Theodore F Logan, Jacob A Eitel, et al.
Nuclear Medicine and Biology|December 25, 2016
Estimation of radiation dosimetry for <sup>68</sup>Ga-HBED-CC (PSMA-11) in patients with suspected recurrence of prostate cancerMark A Green, Jacob A Eitel, James W Fletcher, et al.
Molecular Imaging and Biology|August 21, 2019
[<sup>68</sup>Ga]Ga-P16-093 as a PSMA-Targeted PET Radiopharmaceutical for Detection of Cancer: Initial Evaluation and Comparison with [<sup>68</sup>Ga]Ga-PSMA-11 in Prostate Cancer Patients Presenting with Biochemical RecurrenceMark A Green, Gary D Hutchins, Clinton D Bahler, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 7, 2003
Evaluation of 111In-DTPA-folate as a receptor-targeted diagnostic agent for ovarian cancer: initial clinical resultsBarry A Siegel, Farrokh Dehdashti, David G Mutch, et al.
Urologic Oncology|November 4, 2022
Assessing extra-prostatic extension for surgical guidance in prostate cancer: Comparing two PSMA-PET tracers with the standard-of-careClinton D Bahler, Mark A Green, Mark A Tann, et al.
Nuclear Medicine and Biology|September 23, 2003
Preparation of 66Ga- and 68Ga-labeled Ga(III)-deferoxamine-folate as potential folate-receptor-targeted PET radiopharmaceuticalsCarla J Mathias, Michael R Lewis, David E Reichert, et al.
The Journal of Urology|May 24, 2024
Comparing Magnetic Resonance Imaging and Prostate-Specific Membrane Antigen-Positron Emission Tomography for Prediction of Extraprostatic Extension of Prostate Cancer and Surgical Guidance: A Prospective Nonrandomized Clinical TrialClinton D Bahler, Isamu Tachibana, Mark Tann, et al.
Pageof 2